Patents by Inventor Richard A. Heyman

Richard A. Heyman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7655699
    Abstract: Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, pyrrole, and polyenoic acid derivatives including carbocyclic polyenoic acids. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
    Type: Grant
    Filed: October 22, 1993
    Date of Patent: February 2, 2010
    Assignee: Eisai Inc.
    Inventors: Marcus F. Boehm, Richard A. Heyman
  • Publication number: 20090093546
    Abstract: Methods and compositions for the treatment of anti-estrogen resistant breast cancer using retinoid compounds that are modulators of Retinoid X Receptors are provide.
    Type: Application
    Filed: November 19, 2008
    Publication date: April 9, 2009
    Inventors: William W. Lamph, Eric D. Bischoff, Richard A. Heyman
  • Publication number: 20070238791
    Abstract: Methods and compositions for the treatment of anti-estrogen resistant breast cancer using retinoid compounds that are modulators of Retinoid X Receptors are provided.
    Type: Application
    Filed: June 12, 2007
    Publication date: October 11, 2007
    Inventors: William Lamph, Eric Bischoff, Richard Heyman
  • Patent number: 7259188
    Abstract: Methods and compositions for the treatment of anti-estrogen resistant breast cancer using retinoid compounds which are modulators of Retinoid X Receptors.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: August 21, 2007
    Assignee: Llgand Pharmaceuticals Incorporated
    Inventors: William W. Lamph, Eric D. Bischoff, Richard A. Heyman
  • Publication number: 20060211768
    Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.
    Type: Application
    Filed: October 21, 2005
    Publication date: September 21, 2006
    Inventors: Ronald Evans, David Mangelsdorf, Richard Heyman, Marcus Boehm, Gregor Eichele, Christina Thaller
  • Patent number: 7056954
    Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: June 6, 2006
    Assignees: The Salk Institute for Biological Studies, Baylor College of Medicine, Ligand Pharmaceuticals, Inc.
    Inventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
  • Publication number: 20060106072
    Abstract: Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, and pyrrole derivatives. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
    Type: Application
    Filed: December 13, 2005
    Publication date: May 18, 2006
    Inventors: Marcus Boehm, Richard Heyman
  • Patent number: 6992108
    Abstract: A method for modulating lipid metabolism in a subject by administering 9-cis retinoic acid is presented. The 9-cis retinoic acid is more specific for the retinoid X receptor than is retinoic acid.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 31, 2006
    Assignees: The Salk Institute for Biological Studies, Baylor College of Medicine, Ligand Pharmaceuticals, Inc.
    Inventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
  • Publication number: 20040019072
    Abstract: Dimer-selective RXR modulator compounds having agonist, partial agonist and/or antagonist activity in the context of an RXR homodimer and/or RXR heterodimers are provided. Also provided are pharmaceutical compositions incorporating such dimer-selective RXR modulator compounds and methods for their therapeutic use.
    Type: Application
    Filed: February 5, 2003
    Publication date: January 29, 2004
    Inventors: Stacie Canan-Koch, Chan K. Hwang, Marcus F. Boehm, Beth Ann Badea, Laura J. Dardashti, Lin Zhang, Alex M. Nadzan, Richard A. Heyman, Ranjan Mukherjee, Deepak S. Lala, Luc J. Farmer
  • Publication number: 20040006144
    Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.
    Type: Application
    Filed: June 10, 2003
    Publication date: January 8, 2004
    Applicant: The Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
  • Patent number: 6610883
    Abstract: Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, pyrrole, and polyenoic acid derivatives including carbocyclic polyenoic acids. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
    Type: Grant
    Filed: July 13, 1998
    Date of Patent: August 26, 2003
    Assignee: Ligand Pharmaceuticals, Inc.
    Inventors: Marcus F. Boehm, Richard A. Heyman, Lin Zhi, Chan Kou (Jack) Hwang, Steve White, Alex Nadzan
  • Patent number: 6576676
    Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: June 10, 2003
    Assignees: The Salk Institute for Biological Studies, Baylor College of Medicine, Ligand Pharmaceuticals, Inc.
    Inventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
  • Publication number: 20030105166
    Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.
    Type: Application
    Filed: July 9, 1999
    Publication date: June 5, 2003
    Inventors: RONALD M. EVANS, DAVID J. MANGELSDORF, RICHARD A. HEYMAN, MARCUS F. BOEHM, GREGOR EICHELE, CHRISTINA THALLER
  • Patent number: 6545049
    Abstract: Dimer-selective RXR modulator compounds having agonist, partial agonist and/or antagonist activity in the context of an RXR homodimer and/or RXR heterodimers are provided. Also provided are pharmaceutical compositions incorporating such dimer-selective RXR modulator compounds and methods for their therapeutic use.
    Type: Grant
    Filed: September 2, 1999
    Date of Patent: April 8, 2003
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Stacie Canan-Koch, Chan K. Hwang, Marcus F. Boehm, Beth Ann Badea, Laura J. Dardashti, Lin Zhang, Alex M. Nadzan, Richard A. Heyman, Ranjan Mukherjee, Deepak S. Lala, Luc J. Farmer
  • Patent number: 6521633
    Abstract: This invention relates to methods and compositions for the treatment of non-insulin-dependent diabetes mellitus using an RXR agonist alone or in combination with a PPAR&ggr; agonist such as a thiazolidinedione compound.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: February 18, 2003
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Richard A. Heyman, Rosemary Cesario, Ranjan Mukherjee
  • Publication number: 20030013766
    Abstract: Methods and compositions for the treatment of anti-estrogen resistant breast cancer using retinoid compounds which are modulators of Retinoid X Receptors.
    Type: Application
    Filed: August 27, 2002
    Publication date: January 16, 2003
    Inventors: William W. Lamph, Eric D. Bischoff, Richard A. Heyman
  • Patent number: 6506917
    Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 14, 2003
    Assignee: The Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
  • Publication number: 20020193291
    Abstract: This invention relates to methods and compositions for the treatment of non-insulin-dependent diabetes mellitus using an RXR agonist alone or in combination with a PPAR&ggr; agonist such as a thiazolidinedione compound.
    Type: Application
    Filed: May 7, 2001
    Publication date: December 19, 2002
    Applicant: Ligand Pharmaceuticals
    Inventors: Richard A. Heyman, Rosemary Cesario, Ranjan Mukherjee
  • Patent number: 6320074
    Abstract: Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, and pyrrole derivatives. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.
    Type: Grant
    Filed: October 27, 1998
    Date of Patent: November 20, 2001
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Marcus F. Boehm, Richard A. Heyman, Lin Zhi, Stacie Canan Koch
  • Patent number: 6316404
    Abstract: This invention relates to methods and compositions for the treatment of non-insulin-dependent diabetes mellitus using an RXR agonist alone or in combination with a PPAR&ggr; agonist such as a thiazolidinedione compound.
    Type: Grant
    Filed: December 22, 2000
    Date of Patent: November 13, 2001
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Richard A. Heyman, Rosemary Cesario, Ranjan Mukherjee